**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 85584

**Manuscript Type:** CASE REPORT

**T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report**

Park S *et al.* Venetoclax and decitabine for MPAL

Sungwoo Park, Eun Jeong Jeong, Jung Hun Kang, Gyeong-Won Lee, Se-Il Go, Dong-Hyun Lee, Eun-Ha Koh

**Sungwoo Park, Eun Jeong Jeong, Jung Hun Kang,** Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Gyeongsang National University, Jinju 52727, South Korea

**Gyeong-Won Lee,** Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju 52727, South Korea

**Se-Il Go,** Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon 52828, South Korea

**Dong-Hyun Lee, Eun-Ha Koh,** Department of Laboratory Medicine, Gyeongsang National University, Jinju 52828, South Korea

**Author contributions:** Park S was involved in the conception and design of the study, analyzed the data, and wrote the article; Jeong EJ, Kang JH, LeeDH, Koh EH, and Go SI performed the treatment, acquired the data, and revised the manuscript; Lee GW was involved in the conception and design of the study, critically revised the manuscript for important intellectual content, and gave final approval for the version to be submitted.

**Corresponding author: Gyeong-Won Lee, MD, PhD, Associate Professor,** Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, 79 Gangnam-ro, Jinju-si, Gyeongsangnam-do 52727, South Korea. brightree@naver.com

**Received:** May 25, 2023

**Revised:** July 24, 2023

**Accepted:** August 18, 2023

**Published online:**

**Abstract**

BACKGROUND

Mixed-phenotype acute leukemia (MPAL) is characterized by acute undifferentiated leukemia with blasts co-expressing myeloid and lymphoid antigens. However, consensus regarding the ideal management strategy for MPAL is yet to be established, owing to its rarity.

CASE SUMMARY

A55-year-old male was diagnosed with T/myeloid MPAL. Vincristine, prednisolone, daunorubicin, and L-asparaginase were administered as induction chemotherapy. Septic shock occurred 10 d after induction, and bone marrow examination following recovery from sepsis revealed refractory disease. Venetoclax and decitabine were administered as chemotherapy-free induction therapy to reduce the infection risk. There were no serious infections, including febrile neutropenia, at the end of the treatment. After receiving two additional cycles of venetoclax/decitabine, the patient underwent haploidentical peripheral blood stem-cell transplantation and achieved complete response (CR) to treatment.

CONCLUSION

CR was maintained in a patient with MPAL who underwent haploidentical peripheral blood stem-cell transplantation after additional venetoclax/decitabine cycles.

**Key Words:** Mixed-phenotype acute leukemia; Venetoclax; Decitabine; Case report

Park S, Jeong EJ, Kang JH, Lee GW, Go SI, Lee DH, Koh EH. T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report. *World J Clin Cases* 2023; In press

**Core Tip:** We report a55-year-old male diagnosed with T/myeloid mixed-phenotype acute leukemia (MPAL) who received induction chemotherapy with vincristine, prednisolone, daunorubicin, and L-asparaginase. The patient experienced septic shock 10 days post-induction therapy and received antibiotic therapy to treat extended-spectrum beta-lactamase-positive bacteremia. Bone marrow examination post-sepsis recovery revealed refractory disease. To reduce the infection risk, venetoclax and decitabine were administered as chemotherapy-free induction therapy. After two additional venetoclax/decitabine cycles, the patient underwent haploidentical peripheral blood stem-cell transplantation, subsequently achieving complete response. This is the third report documenting the successful treatment of refractory T/myeloid MPAL with venetoclax and a hypomethylating agent.

**INTRODUCTION**

The term "mixed-phenotype acute leukemia" (MPAL) refers to a heterogeneous group of uncommon acute leukemias accounting for ≤ 5% of all acute leukemias, characterized by co-expression of myeloid and lymphoid antigens on the same blasts or by the presence of two separate cell populations expressing various lineage traits[1]. In 2022, the World Health Organization (WHO) recognized T/myeloid MPAL as one of five MPAL subtypes of acute leukemia of uncertain lineage[2]. The prognosis and consequences of MPAL are worse than those of standard-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)[1]. The prognosis is exceedingly dismal for patients with relapsed/refractory (R/R) AML who are unsuitable candidates for intensive chemotherapy regimens or allogeneic hematopoietic stem-cell transplantation (allo-HSCT).

Given the rarity of MPAL, an ideal strategy for disease management is yet to be established. AML- and ALL-based regimens should be prospectively validated, given the inevitable bias inherent in retrospective studies and small case series. Currently, an ALL-like induction protocol is recommended, then allogeneic stem cell transplantation (allo-SCT) is performed after the initial complete remission. Moreover, the treatment strategy has not been well established since introducing the concept of MPAL. Salvage treatment for relapsed/refractory (R/R) acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS), remains a major concern. Currently, allo-HSCT is the only treatment strategy for ALAL-NOS; however, the prognosis remains poor if complete response (CR) is not achieved before allo-HSCT[3]. Chemotherapy is ineffective for ALAL-NOS. Therefore, salvage treatments are required to enhance the CR before allo-HSCT.

To the best of our knowledge, the current report is the third instance of successful treatment with venetoclax and a hypomethylating agent (HMA) in a patient with refractory T/myeloid MPAL. Future studies should examine the effectiveness of this approach.

**CASE PRESENTATION**

***Chief complaints***

A 55-year-old male patient with dizziness was admitted to the hospital.

***History of present illness***

Beginning one week prior, the patient developed dizziness and difficulty breathing when climbing stairs.

***History of past illness***

He had a history of hypertension and epilepsy and was taking levetiracetam.

***Personal and family history***

No specific findings were recorded.

***Physical examination***

There were no specific findings on palpation of the spleen, the face appeared markedly pale, and there were no bruises on the skin.

***Laboratory examinations***

Neutropenia (1.12 × 103/mm3), anemia (4.0 g/dL), and thrombocytopenia (12 × 103/mm3) were detected in peripheral blood. Figure 1 describes the findings of the bone marrow examination. Flow cytometry showed the expression of cMPO+, CD 13+, CD33+, CD64+, CD117+, CD34+, and high cytoplasmic CD3. Chromosomal karyotyping revealed a 48, XY, add(11)(q23), add(12)(p13).-20,-22,+4mar karyotype. Fluorescence *in situ* hybridization revealed KMT2A positivity. Next-generation sequencing results were negative for the BCR-ABL gene or other mutations.

***Imaging examinations***

No specific findings were observed on the chest X-ray.

**FINAL DIAGNOSIS**

A diagnosis of T/myeloid MPAL was confirmed by bone marrow aspiration, which was suggestive of acute leukemia.

**TREATMENT**

Vincristine, prednisolone, daunorubicin, and L-asparaginase (VPDL) were administered as induction therapy. Ten days after initiating induction chemotherapy, the patient developed septic shock with hypotension (blood pressure 80/40 mmHg) and high fever (39.2°C). Effective antibiotics (colistin, meropenem, and ciprofloxacin) were initiated after a blood culture-confirmed bacteremia caused by extended-spectrum beta-lactamase-positive *Klebsiella pneumoniae*. Bone marrow examination after recovery from sepsis revealed refractory disease, and flow cytometry for minimal residual disease detected the presence of blasts (expressing cCD3+, CD33+, and CD34+). To reduce the risk of infection, venetoclax (Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4-28: 100 mg), posaconazole, and decitabine (20 mg/m2, mixed with normal saline, 150 mL for 5 d) were administered as chemotherapy-free induction therapy. Thereafter, no serious infection, such as febrile neutropenia, occurred. The patient underwent haploidentical peripheral blood cell transplantation after two additional cycles of venetoclax/decitabine.

**OUTCOME AND FOLLOW-UP**

The patient achieved CR one year post-HSCT. Figure 2 summarizes the absolute neutrophil counts from initiating the VPDL regimen to the end of the second venetoclax + decitabine cycle. Neutropenia resolved early during the second cycle. The ANC was less than 500 for two weeks and did not decline to less than 100.

**DISCUSSION**

Considering patients with MPAL, the three common treatment modalities include ALL-directed, AML-directed, and hybrid strategies (ALL plus AML). Based on retrospective data, experts favor ALL-based chemotherapy over AML-based chemotherapy owing to its superior remission rates[4,5]. However, accumulated data are retrospective, and validation in multicenter, prospective clinical trials is pending. Additionally, adverse effects associated with conventional treatment modalities, such as deadly infections and bleeding, present a persistent challenge to the survival of patients with MPAL[6].A recent meta-analysis of 1300 patients found that patients who received an induction regimen with ALL-directed therapy were significantly more likely to achieve CR and were twice as likely to survive than patients who received an AML-directed regimen. The study included case reports of patients with MPAL (WHO) or biphenotypic leukemia (European Group for the Immunological Classification of Leukemias) as well as small international series and case reports. A multivariate examination of comprehensive clinical data, including the type of therapy, MPAL subgroup, and patient age, revealed that the overall survival (OS) rates between ALL and AML induction regimens did not differ (3-year OS, 48, 6.9% *vs* 47, 5.0%, respectively).

Hematopoietic stem cell transplantation has been shown to substantially increase the 5-year survival rate in patients with MPAL[7], and bridging therapy should ideally be associated with less toxicity and complications. Patients' survival was demonstrated to be considerably decreased by a combination regimen (a mix of ALL and AML therapy) (3-year OS, 23% 8.6%, *P* = 0.001), probably because of higher toxicity[4].

In November 2018, the Food and Drug Administration approved the administration of venetoclax along with an HMA in older or more vulnerable patients with recently diagnosed AML[8]. Venetoclax, a powerful oral BCL-2 inhibitor, has shown clinical success in treating various hematologic cancers[9]. In hematologic malignancies, HMAs act by inhibiting deoxyribonucleic acid (DNA) methyltransferase-1, which results in DNA demethylation, cell differentiation, or apoptosis[10]. The pathogenesis of myeloid and lymphoid malignancies is facilitated by aberrant DNA methylation, which has been linked to the possibility that hematopoietic stem cells in MPAL undergo aberrant transformation[11]. According to recent real-world evidence, decitabine with venetoclax can yield superior outcomes to decitabine monotherapy in patients with AML[12].

Moreover, several clinical studies have indicated the potential feasibility of decitabine in B-cell ALL and T-cell ALL, especially R/R ALL, although data in this field remain limited[13–17]. Some case reports have indicated the efficacy of venetoclax in patients with MPAL[18]. The characteristics of T/myeloid MPAL are distinct from those of B/myeloid MPAL, another type of MPAL. A case of T/myeloid MPAL relapse following effective treatment of allo-HSCT with venetoclax + decitabine[19]. Given the challenges in conducting clinical trials targeting only the T/myeloid MPAL patient population, we present the third case report of a patient with T/myeloid MPAL successfully treated with venetoclax and an HMA.

**CONCLUSION**

Herein, we present a patient with MPAL who experienced serious complications with standard chemotherapy. Subsequently, the patient received combination therapy with venetoclax and HMA and underwent hematopoietic stem cell transplantation. Therefore, it is necessary to establish whether combination therapy with venetoclax and HMA could be beneficial as bridging therapy pre-transplantation. Accordingly, future investigations should compare the potential of venetoclax and HMA with traditional chemotherapy in patients who can eventually undergo transplantation.

**ACKNOWLEDGMENTS**

The authors gratefully acknowledge the patient and his family for their cooperation and kind help.

**REFERENCES**

1 **Shi R**, Munker R. Survival of patients with mixed phenotype acute leukemias: A large population-based study. *Leuk Res* 2015; **39**: 606-616 [PMID: 25858895 DOI: 10.1016/j.leukres.2015.03.012]

2 **Khoury JD**, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia* 2022; **36**: 1703-1719 [PMID: 35732831 DOI: 10.1038/s41375-022-01613-1]

3 **Shimizu H**, Saitoh T, Machida S, Kako S, Doki N, Mori T, Sakura T, Kanda Y, Kanamori H, Miyawaki S, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. *Eur J Haematol* 2015; **95**: 455-460 [PMID: 25605541 DOI: 10.1111/ejh.12516]

4 **Maruffi M**, Sposto R, Oberley MJ, Kysh L, Orgel E. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. *Leukemia* 2018; **32**: 1515-1528 [PMID: 29550836 DOI: 10.1038/s41375-018-0058-4]

5 **Wolach O**, Stone RM. Optimal therapeutic strategies for mixed phenotype acute leukemia. *Curr Opin Hematol* 2020; **27**: 95-102 [PMID: 31913151 DOI: 10.1097/MOH.0000000000000570]

6 **Xu XQ**, Wang JM, Lü SQ, Chen L, Yang JM, Zhang WP, Song XM, Hou J, Ni X, Qiu HY. Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. *Haematologica* 2009; **94:** 919-927 [PMID: 19454497 DOI: 10.3324/haematol.2008.003202]

7 **Munker R**, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W; Center for International Blood and Marrow Transplant Research. Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. *Biol Blood Marrow Transplant* 2016; **22**: 1024-1029 [PMID: 26903380 DOI: 10.1016/j.bbmt.2016.02.013]

8 **DiNardo CD**, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. *Lancet Oncol* 2018; **19**: 216-228 [PMID: 29339097 DOI: 10.1016/S1470-2045(18)30010-X]

9 **Eyre TA**, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, Cross M, Forconi F, Shah N, Chasty R, Hart A, Broom A, Marr H, Patten PEM, Dann A, Arumainathan A, Munir T, Shankara P, Bloor A, Johnston R, Orchard K, Schuh AH, Fox CP; the UK CLL Forum. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. *Br J Haematol* 2019; **185**: 656-669 [PMID: 30768675 DOI: 10.1111/bjh.15802]

10 **Das M**. Venetoclax with decitabine or azacitidine for AML. *Lancet Oncol* 2018; **19**: e672 [PMID: 30392809 DOI: 10.1016/S1470-2045(18)30824-6]

11 **Eckstein OS,** Wang L, Punia JN, Kornblau SM, Andreef M, Wheeler DA, Goodell MA. Mixed phenotype acute leukemia (MPAL) has a high frequency of mutations in epigenetic regulatory genes: results from whole exome sequencing. *Blood* 2014; **124:** 3560 [DOI: 10.1182/blood.V124.21.3560.3560]

12 **Kwag D**, Cho BS, Bang SY, Lee JH, Min GJ, Park SS, Park S, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Lee JW, Kim HJ. Venetoclax with decitabine *vs* decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. *Blood Cancer J* 2022; **12**: 169 [PMID: 36529771 DOI: 10.1038/s41408-022-00770-x]

13 **Paulson K**, Kumar R, Ahsanuddin A, Seftel MD. Azacytidine as a novel agent in the treatment of acute lymphoblastic leukemia. *Leuk Lymphoma* 2011; **52**: 134-136 [PMID: 20858102 DOI: 10.3109/10428194.2010.512965]

14 **Cui JK**, Xiao Y, You Y, Shi W, Li Q, Luo Y, Jiang L, Zhong ZD. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. *J Huazhong Univ Sci Technolog Med Sci* 2017; **37**: 693-698 [PMID: 29058281 DOI: 10.1007/s11596-017-1790-0]

15 **Burke MJ**, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. *Am J Hematol* 2014; **89**: 889-895 [PMID: 24891274 DOI: 10.1002/ajh.23778]

16 **Benton CB**, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. *Br J Haematol* 2014; **167**: 356-365 [PMID: 25066676 DOI: 10.1111/bjh.13050]

17 **Garcia-Manero G,** Thomas DA, Rytting ME, O’Brien S, Franklin ARK, Borthakur G, Kwari M, Dara S, Yang H, Kantarjian H. Final report of a phase I trial of decitabine with or without hyperCVAD in relapsed acute lymphocytic leukemia (ALL). *Blood* 2010; **116:** 867 [DOI: 10.1182/blood.V116.21.867.867]

18 **Wu X**, Zhang J, Chen Q, Zhou L, Li M, Qiu H, Sun A, Wu D. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia. *Br J Haematol* 2020; **189**: e200-e204 [PMID: 32242923 DOI: 10.1111/bjh.16622]

19 **Klocke H**, Dong ZM, O'Brien C, Burwick N, Richard RE, Wu DY, Chauncey TR, Graf SA. Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS). *Case Rep Hematol* 2020; **2020**: 8811673 [PMID: 33101740 DOI: 10.1155/2020/8811673]

**Footnotes**

**Informed consent statement:** The requirement for informed consent was waived because the analysis used completely anonymous data; consent was obtained before performing any medical investigation or the start of treatment as required.

**Conflict-of-interest statement:** All the authors declare that they have no conflict of interest to disclose.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 25, 2023

**First decision:** June 15, 2023

**Article in press:**

**Specialty type:** Hematology

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Elpek GO, Turkey; Gica N, Romania **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**

****

**Figure 1 Leukemic blasts in** **bone marrow aspiration and biopsy at the initial diagnosis of mixed-phenotype acute leukemia.** A: Bone marrow aspiration smear (Wright-Giemsa stain, 400×); B: Bone marrowbiopsy section (hematoxylin and eosin stain, 100×); C: Bone marrowbiopsy section with immunohistochemical staining of CD34 (100×); D: Bone marrowbiopsy section with immunohistochemical staining of CD3 (100×); E: Bone marrowbiopsy section with immunohistochemical staining of myeloperoxidase (100×) with similar distribution.

****

**Figure 2 Summary of the absolute neutrophil counts from initiating vincristine, prednisolone, daunorubicin, and l-asparaginase therapy to the end of the second venetoclax/decitabine cycle.** VDPL: Vincristine, prednisolone, daunorubicin, and l-asparaginase.